Meet ApplyKite Twin, the application assistant that learns with you

Meet your Twin, it learns with you

Your Twin learns with you

Launch week codes:30% off annual Pro20% off monthly Pro

Ends in00h00m00s

Ahmad Tarhini

Senior Member, Professor

H Lee Moffitt Cancer Center and Research Institute

United States

Research Interests

Explore related searches

Professors in United States Professors in Immunology Immunology professors in United States

Articles (14)

Year:

2026

Year:

2026

Year:

2026

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Collaborators (8)

Jesus Gonzalez Bosquet

Iowa State University

UNITED STATES

View details

Theodore Logan

Associate Professor Clinical Medicine

Indiana University School of Medicine

UNITED STATES

View details

Bartosz Chmielowski

Ronald Reagan UCLA Medical Center

UNITED STATES

View details

William LaFramboise

Chief Genomics Technology Officer, Professor

Alleghgeny Health Network

UNITED STATES

View details

Michael Schell

Senio Member

H Lee Moffitt Cancer Center and Research Institute

UNITED STATES

View details

Dung-Tsa Chen

H Lee Moffitt Cancer Center and Research Institute

UNITED STATES

View details

Timothy Yap

The University of Texas MD Anderson Cancer Center

UNITED STATES

View details

Casey Cosgrove

Ohio State University

UNITED STATES

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Ahmad Tarhini

Research Interests

Explore related searches

Articles (14)

Predicting immune-related thyroiditis using polygenic risk scores in patients with advanced melanoma

Linavonkibart and pembrolizumab in immune checkpoint blockade-resistant advanced solid tumors: a phase 1 trial

Neoadjuvant lenvatinib plus pembrolizumab in Merkel cell carcinoma: an investigator-initiated, open-label phase II trial

Training, Validating, and Testing Machine Learning Prediction Models for Endometrial Cancer Recurrence

Integrative Immune Signature of Complementary Circulating and Tumoral Biomarkers Maximizes the Predictive Power of Adjuvant Immunotherapeutic Benefits in High-risk Melanoma

A Retrospective Cohort Study of Physical Activity and Survival in Patients Treated with Immune Checkpoint Inhibitors

Adjuvant nivolumab and relatlimab in stage III/IV melanoma: the randomized phase 3 RELATIVITY-098 trial

Neoadjuvant PD-1 and LAG-3-targeting bispecific antibody and other immune checkpoint inhibitor combinations in resectable melanoma: the randomized phase 1b/2 Morpheus-Melanoma trial

Monoclonal antibodies as adjuvant therapies for resected melanoma

Effector T cells under hypoxia have an altered transcriptome similar to tumor-stressed T cells found in non-responsive melanoma patients

Neoadjuvant Intratumoral Plasmid IL-12 Electro-Gene-Transfer and Nivolumab in Patients with Operable, Locoregionally Advanced Melanoma

Durability of response to immune checkpoint blockade following treatment discontinuation and efficacy of rechallenge in advanced Merkel cell carcinoma

Combination Dabrafenib and Trametinib Versus Combination Nivolumab and Ipilimumab for Patients With Advanced BRAF-Mutant Melanoma: The DREAMseq Trial—ECOG-ACRIN EA6134

Neoadjuvant Therapy in Melanoma: Where Are We Now?

Collaborators (8)

Jesus Gonzalez Bosquet

Theodore Logan

Bartosz Chmielowski

William LaFramboise

Michael Schell

Dung-Tsa Chen

Timothy Yap

Casey Cosgrove

Make your next move.